Skip to main content

Table 1 Relationship between the expressions of PD-1, PD-L1 and PD-L2 and clinicopathological parameters in the whole cohort

From: Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma

  PD-1 P Value PD-L1 P Value PD-L2 P Vaule
Positive Negative Positive Negative Positive Negative
Total 76(46.6) 87(53.4)   53(32.5) 110(67.5)   43(26.4) 120(73.6)  
Age, n (%)    0.65    0.27    0.35
 < 50y 27(49.1) 28(50.9)   21(38.2) 34(61.8)   17(30.9) 38(69.1)  
 ≥ 50y 49(45.4) 59(54.6)   32(29.6) 76(70.4)   26(24.1) 82(75.9)  
Gender, n (%)    0.97    0.18    0.16
 Male 50(46.7) 57(53.3)   31(29.0) 76(71.0)   32(29.9) 75(70.1)  
 Female 26(46.4) 30(53.6)   22(39.3) 34(60.7)   11(19.6) 45(80.4)  
ISUP, n (%)    0.13    0.81    0.57
 < 3 12(34.3) 23(65.7)   9(25.7) 26(74.3)   7(20.0) 28(80.0)  
 ≥ 3 55(50.0) 55(50.0)   40(36.4) 70(63.6)   30(27.3) 80(72.7)  
Histological Type, n(%)    0.22    0.78    0.52
 ccRCC 56(44.1) 71(55.9)   42(33.1) 85(66.9)   32(25.2) 95(74.8)  
 Non-ccRCC 20(55.6) 16(44.4)   11(30.6) 25(69.4)   11(30.6) 25(69.4)  
Pathology, n (%)
 Sarcoma 7(87.5) 1(12.5) 0.07 4(50.0) 4(50.0) 0.66 3(37.5) 5(62.5) 0.69
 Necrosis 19(63.3) 11(36.7) 0.59 11(36.7) 19(63.3) 0.33 6(20.0) 24(80.0) 0.09
Nephrectomy    0.22    0.18    0.02
 Yes 68(49.6) 69(50.4)   48(35.0) 89(65.0)   39(28.5) 98(71.5)  
 No 7(35.0) 13(65.0)   4(20.0) 16(80.0)   1(5.0) 19(95.0)  
ECOG, n (%)    0.77    0.15    0.62
 0–1 53(47.3) 59(52.7)   42(37.5) 70(62.5)   29(25.9) 83(74.1)  
 ≥ 2 20(50.0) 20(50.0)   10(25.0) 30(75.0)   12(30.0) 28(70.0)  
IMDC, n (%)    0.11    0.26    0.83
 Low 10(30.3) 23(69.7)   9(27.3) 24(72.7)   9(27.3) 24(72.7)  
 Intermediate 41(51.3) 39(48.8)   29(36.3) 51(63.7)   19(23.8) 61(76.2)  
 High 15(51.7) 14(48.3)   6(20.7) 23(79.3)   6(20.7) 23(79.3)  
T stage, n (%)    0.691    0.09    0.91
 < 3 43(58.9) 30(41.1)   31(42.5) 42(57.5)   20(27.4) 53(72.6)  
 ≥ 3 14(43.8) 18(56.2)   5(22.7) 17(77.3)   6(27.3) 16(72.7)  
Metastasis, n (%)
 Lung 13(54.2) 11(45.8) 0.46 11(45.8) 13(54.2) 0.21 7(29.2) 17(70.8) 0.91
 Lymph node 37(77.1) 11(22.9) < 0.001 23(47.9) 25(52.1) 0.02 18(37.5) 30(62.5) 0.09
 Bone 18(43.9) 23(56.1) 0.64 6(14.6) 35(85.4) 0.002 10(24.4) 31(75.6) 0.54
 Brain 2(10.5) 17(89.5) 0.001 7(36.8) 12(63.2) 0.82 2(10.5) 17(89.5) 0.07
 Adrenal 1(16.7) 5(83.3) 0.13 1(16.7) 5(83.3) 0.35 3(50.0) 3(50.0) 0.23
 Viscera 3(18.8) 13(81.3) 0.02 5(31.3) 11(68.8) 0.78 6(37.5) 10(62.5) 0.38
 Others 8(40.0) 12(60.0) 0.49 7(35.0) 13(65.0) 0.96 3(15.0) 17(85.0) 0.16
Treatment, n (%)
 Cytokine 11(50.0) 11(50.0) 0.76 4(18.2) 18(81.8) 0.09 8(36.4) 14(63.6) 0.23
 Targeted therapy 32(50.0) 32(50.0) 0.49 24(37.5) 40(62.5) 0.54 15(23.4) 49(76.6) 0.83
 Radiotherapy 7(50.0) 7(50.0) 0.81 4(28.6) 10(71.4) 0.69 3(21.4) 11(78.6) 0.79
 Chemotherapy 4(50.0) 4(50.0) 0.89 4(50.0) 4(50.0) 0.34 3(37.5) 5(62.5) 0.39
  1. Abbreviations: ISUP International Society of Urological Pathology, ccRCC clear cell renal cell carcinoma, ECOG Eastern Cooperative Oncology Group, IMDC International Metastatic Renal-Cell Carcinoma Database Consortium